二价 mRNA 疫苗预防 COVID-19 相关急诊或紧急护理就诊及住院效果的早期估计——VISION 网络,九州,2022 年 9 月至 11 月
2022 年 9 月 13 日至 11 月 18 日,VISION 网络在九州评估了免疫功能正常成人接种二价 mRNA 加强针(完成 2、3 或 4 剂单价疫苗后)的疫苗有效性。与未接种相比,二价加强针对 COVID-19 相关急诊/紧急护理就诊的有效性为 56%,对住院的有效性为 57%;与仅接种单价疫苗相比,相对保护随时间推移而增加。所有符合条件者应保持最新 COVID-19 疫苗接种,包括接种二价加强针。
要点
- 二价加强针对 COVID-19 相关急诊/紧急护理就诊的有效性:与未接种相比为 56%。
- 二价加强针对 COVID-19 相关住院的有效性:与未接种相比为 57%。
- 与仅接种单价疫苗相比,二价加强针提供额外保护,相对保护随末剂单价疫苗接种时间推移而增加。
核心结论
- 在完成 2、3 或 4 剂单价疫苗后接种二价疫苗,与未接种相比可有效预防需医疗就诊的 COVID-19,与仅既往接种单价疫苗相比提供额外保护,相对保护随末剂单价疫苗接种时间推移而增加。
研究设计与样本
- VISION 网络于 2022 年 9 月 13 日至 11 月 18 日在九州评估二价 mRNA 加强针(完成 2、3 或 4 剂单价疫苗后)的疫苗有效性,对象为年龄≥18 岁、因 COVID-19 样疾病就诊于急诊/紧急护理或住院的免疫功能正常成人。
主要发现
- 二价加强针(完成 2、3 或 4 剂单价疫苗后)对 COVID-19 相关急诊/紧急护理就诊的有效性:与未接种相比为 56%,与仅接种单价疫苗且末剂在 2-4 个月前相比为 31%,与仅接种单价疫苗且末剂在≥11 个月前相比为 50%。
- 二价加强针(完成 2、3 或 4 剂单价疫苗后)对 COVID-19 相关住院的有效性:与未接种相比为 57%,与仅接种单价疫苗且末剂在 5-7 个月前相比为 38%,与仅接种单价疫苗且末剂在≥11 个月前相比为 45%。
临床怎么用
- 所有符合条件者应保持最新推荐的 COVID-19 疫苗接种,包括接种二价加强针。
- 个人还应考虑采取额外预防措施以避免本冬季呼吸道疾病,如在公共室内空间佩戴口罩,尤其在 COVID-19 社区水平高的地区。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of the sequenced viral genomes in the United States, with further Omicron sublineage diversification through November 2022.* Bivalent mRNA vaccines contain an ancestral SARS-CoV-2 strain component plus an updated component of the Omicron BA.4/BA.5 sublineages. On September 1, 2022, a single bivalent booster dose was recommended for adults who had completed a primary vaccination series (with or without subsequent booster doses), with the last dose administered ≥2 months earlier (1). During September 13-November 18, the VISION Network evaluated vaccine effectiveness (VE) of a bivalent mRNA booster dose (after 2, 3, or 4 monovalent doses) compared with 1) no previous vaccination and 2) previous receipt of 2, 3, or 4 monovalent-only mRNA vaccine doses, among immunocompetent adults aged ≥18 years with an emergency department/urgent care (ED/UC) encounter or hospitalization for a COVID-19-like illness.† VE of a bivalent booster dose (after 2, 3, or 4 monovalent doses) against COVID-19-associated ED/UC encounters was 56% compared with no vaccination, 31% compared with monovalent vaccination only with last dose 2-4 months earlier, and 50% compared with monovalent vaccination only with last dose ≥11 months earlier. VE of a bivalent booster dose (after 2, 3, or 4 monovalent doses) against COVID-19-associated hospitalizations was 57% compared with no vaccination, 38% compared with monovalent vaccination only with last dose 5-7 months earlier, and 45% compared with monovalent vaccination only with last dose ≥11 months earlier. Bivalent vaccines administered after 2, 3, or 4 monovalent doses were effective in preventing medically attended COVID-19 compared with no vaccination and provided additional protection compared with past monovalent vaccination only, with relative protection increasing with time since receipt of the last monovalent dose. All eligible persons should stay up to date with recommended COVID-19 vaccinations, including receiving a bivalent booster dose. Persons should also consider taking additional precautions to avoid respiratory illness this winter season, such as masking in public indoor spaces, especially in areas where COVID-19 community levels are high.
引用
- Tenforde MW, Weber ZA, Natarajan K, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36580430. doi:10.15585/mmwr.mm715152e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。